RxDoctor Payments Data

Jeremy Tan, MD

Ophthalmic Plastic and Reconstructive Surgery · Oklahoma City, OKNPI 1124387626

Payments from drug & device makers

$49,683in general payments, 2019–2025

Across 146 payments — averaging $340.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$33K
  • Kerecis Limited$15K
  • Axogen$257
  • AbbVie$226
  • Merz Pharmaceuticals, LLC$197
  • Biotissue Holdings Inc.$186
  • plus $720 from 12 others
$16,050in research payments, 2019–2025

Across 1 payment — averaging $16,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Kerecis Limited$16K

What the payments were for

  • Consulting fees$1,4883%
  • Speaking & faculty fees$36,31873%
  • Travel & lodging$4,2439%
  • Food & beverage$5,05110%
  • Education$2,5835%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$351,727
Medicare patients
470
Services billed
3,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base428$4,562
ValacyclovirValacyclovir Hcl18$383
Doxycycline Monohydrate29$344
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha25$327
Ketorolac Tromethamine17$294
Cephalexin55$267
Fluticasone Propionate17$226
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate11$168
Methylprednisolone16$110

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →